Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Authors
Thistlethwaite, Fiona CElkord, Eyad
Griffiths, Richard W
Burt, Deborah J
Shablak, Alaaeldin
Campbell, John D M
Gilham, David E
Austin, Eric B
Stern, Peter L
Hawkins, Robert E
Affiliation
Cancer Research UK Department of Medical Oncology, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, UK. fthistlethwaite@PICR.man.ac.ukIssue Date
2008-05
Metadata
Show full item recordAbstract
PURPOSE: CD4(+)CD25(+) regulatory T (T(reg)) cells are present in increased numbers in patients with advanced cancer and CD25(+) T cell depletion potentiates tumour immunity in animal models. The aim of this study was to assess the feasibility and safety of adoptive transfer of CD25(+) depleted autologous T cells in patients with advanced renal cell carcinoma and to examine resulting changes in lymphocyte subsets. PATIENTS AND METHODS: Six patients with advanced renal cell carcinoma underwent leukapheresis followed by conditioning chemotherapy with cyclophosphamide and fludarabine. The autologous leukapheresis product was depleted of CD25(+) cells using CliniMACS System then re-infused into the patient. RESULTS: Efficient CD25(+) depletion from all leukapheresis products was achieved and 0.55-5.87 x 10(7)/kg CD3(+) cells were re-infused. Chemotherapy related haematological toxicity was observed, but blood counts recovered in all patients allowing discharge after a mean inpatient stay of 21 days. One patient subsequently developed a rapidly progressive neurological syndrome. A transient reduction in CD25(+) subset was noted in the peripheral blood of 5 out of 6 patients with evidence of increased T cell responses to PHA in 4 out of 6 patients. One patient showed increased specific proliferative responses to the tumour associated antigen h5T4 coinciding with the nadir of T(reg) cells. CONCLUSIONS: Given the transient nature of the reduction in CD25(+) subset and the observed toxicity there is a need to explore further strategies to improve the safety and efficacy of this approach. Nevertheless, the results provide proof of concept in potentiation of tumour antigen T cell responses when T(reg) cell levels are depleted.Citation
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. 2008, 57 (5):623-34 Cancer Immunol. Immunother.Journal
Cancer Immunology, ImmunotherapyDOI
10.1007/s00262-007-0400-6PubMed ID
17899077Type
ArticleLanguage
enISSN
0340-7004ae974a485f413a2113503eed53cd6c53
10.1007/s00262-007-0400-6
Scopus Count
Related articles
- A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
- Authors: Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW
- Issue date: 2003 Sep 1
- Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
- Authors: Powell DJ Jr, Parker LL, Rosenberg SA
- Issue date: 2005 Jul-Aug
- Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma.
- Authors: Zhang CH, Huang Y
- Issue date: 2016
- Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
- Authors: Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, Secondino S, Schiavetto I, Caliogna L, Locatelli F, Libri V, Pession A, Tonelli R, Maccario R, Siena S, Pedrazzoli P
- Issue date: 2012 Jan
- Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
- Authors: Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H
- Issue date: 2007 Apr